A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

Clinical trial NCT02670213 · COMPLETED

Trial details

NCT number: NCT02670213
Sponsor: Novo Nordisk A/S
Status: COMPLETED
Study type: OBSERVATIONAL

Congenital Bleeding Disorder Congenital FXIII Deficiency

Start date: 2016-03-16
Primary completion: 2024-09-30
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.